Developer docs
API playgroundTry for free, no card

Search company profiles

BioCurate

Full company profile

uuid000v5iq

Namestring
BioCurate
Legal namestring
BioCurate
Websiteurl
biocurate.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

BioCurate is an Australian not-for-profit joint venture, formed in 2019 by the University of Melbourne and Monash University with the support of the Victorian State Government, whose mission is to identify promising biomedical research discoveries from these institutions and advance them into high-quality pre-clinical candidates for novel human therapeutics. It is operationally independent, headquartered in Carlton, Melbourne, and staffed by a small team (1-10 employees) of senior drug development professionals whose collective track record includes more than 170 years of biotech/pharma experience, 13 INDs, 30 therapeutics currently in the clinic, and more than $2.4 billion in cumulative deal value.

BioCurate's core offering is a project evaluation and due diligence service combined with a Proof of Concept Fund that provides up to $500,000 per project to generate industry-standard experimental validation and de-risk early-stage therapeutic assets. Its active portfolio comprises four Portfolio projects and nine Proof of Concept projects spanning oncology, neurological disease, cardiovascular disease, and other indications. The organisation also publishes an extensive library of educational fact sheets covering IP strategy, target validation, antibody validation, FDA guidance, Target Product Profile construction, and valuation frameworks, and participates in industry events such as BIO International Convention and the Business of Regenerative Medicine Asia Pacific Symposium.

BioCurate does not earn commercial revenue in the traditional sense; it is funded by its founding universities and the Victorian State Government, supplemented by matching co-funding from the MTPConnect Biomedical Translation Bridge Program (up to $1 million per project). Its go-to-market is community-led and researcher-focused, engaging Monash and University of Melbourne investigators through information sessions, pipeline reviews, and a formal BioCurate Opportunity Assessment process, with the objective of licensing or spinning out industry-ready assets into the global biopharmaceutical pipeline.

Short descriptiontext

BioCurate is a not-for-profit joint venture of the University of Melbourne and Monash University that funds and advances early-stage biomedical research from these institutions into pre-clinical therapeutic candidates. It offers a Proof of Concept Fund (up to $500,000 per project), due diligence, and global industry linkages to academic researchers in Victoria, Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParkville, Australia
HQ citystring
Parkville
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug development translation, preclinical research services, biomedical translation services, therapeutic development support, academic-industry bridge
Industry4 codes
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology Translation Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Not-for-profit translation entity
TypeLicensing Royalties
Description

BioCurate is a purpose-built, not-for-profit company designed to help achieve impact from university research. They provide funding, expertise, and networks to translate discoveries into industry-ready assets. They do not generate revenue in the traditional sense but are operationally independent with support from founding universities and Victorian Government.

biocurate.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioCurate identifies promising biomedical research discoveries from Monash University and the University of Melbourne and advances them into high-quality pre-clinical candidates for novel human therapeutics. The company provides funding (Proof of Concept Fund up to $500,000), expert evaluation services, and access to global biopharmaceutical networks to translate early-stage academic discoveries into industry-ready therapeutic assets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • More than 170 years of combined biotech/pharma industry experience
+3 more records
Product overview1 text field

BioCurate is a not-for-profit joint venture between Monash University and the University of Melbourne, supported by the Victorian State Government, that provides translational drug development services. The company offers a Proof of Concept Fund (up to $500,000 for early-stage validation), manages a portfolio of therapeutic projects spanning oncology and neurological diseases, and provides educational resources including fact sheets on IP strategy, target validation, unmet medical need, FDA guidance, and drug development best practices. BioCurate's core offering is its project evaluation and due diligence services that bridge academia and industry.

Product and service2 records
1Proof of Concept Fund
CategoryFunding Program
Description

A funding program that supports early-stage therapeutic projects with up to $500,000 to provide industry-standard experimental validation, generate compelling data, de-risk projects, and propel them to the next value inflection point. Targeted at researchers from Monash University, University of Melbourne, and affiliated Medical Research Institutes.

2Project Evaluation and Due Diligence Services
CategoryTranslational Research Services
Description

Formal, rigorous process for project review and investment decision-making including initial screening, investigator meetings, due diligence, and Investment Committee review for therapeutic development projects. Targeted at academic researchers submitting therapeutic candidates for advancement.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-01
Description

MTPConnect operates the Biomedical Translation Bridge (BTB) Program in partnership with BioCurate, UniQuest, Medical Device Partnering Program, and Bridge/BridgeTech programs. The BTB Program provides up to $1 million in matching funding to nurture translation of new therapies, technologies, and medical devices through proof of concept.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UniQuest is a partner in the Biomedical Translation Bridge (BTB) Program operated by MTPConnect, working with BioCurate and other partners to support translation of therapeutic discoveries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Part of of the BTB Program ecosystem supporting translation of medical technologies alongside therapeutics.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CCRM Australia co-hosted the Business of Regenerative Medicine Asia Pacific Symposium with NSW Stem Cell Network. BioCurate CEO presented at this event focused on regenerative medicine translation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Co-host of Business of Regenerative Medicine Asia Pacific Symposium with CCRM Australia, bringing together organizations in the regenerative medicine field.

6Monash University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding partner of BioCurate joint venture. Contributes research discoveries and academic expertise to the translation partnership.

biocurate.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding partner of BioCurate joint venture. Contributes research discoveries and academic expertise to the translation partnership.

8Global biopharmaceutical companies
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioCurate has developed linkages with key global biopharmaceutical companies, providing valuable advice and insight to guide research and give projects the best opportunity to progress in the translation process.

biocurate.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Australian biotech spun out of Monash University and a former employer of BioCurate's Head of Drug Development, Chacko Joseph. It illustrates the type of spin-out entity that BioCurate's translation model is designed to generate and support.

2Therapeutic Innovation Australia (TIA)
TypeOthers
Description

National infrastructure provider supporting translational research capabilities across Australia. It is an enabler of the same translational ecosystem BioCurate operates in, rather than a direct competitor, but provides comparable services (capability access, project support) to overlapping researcher segments.

TypeRegional player
Description

Flinders University-based program that helps Australian researchers and clinicians translate medical device concepts. It is a co-partner in the BTB Program with BioCurate and UniQuest and operates a comparable academia-industry bridging model in the medical device niche.

TypeDirect peer
Description

University of Queensland's main commercialization and translation entity. Operates the same academia-to-industry bridge model as BioCurate and is a co-partner in MTPConnect's BTB Program, making it the closest direct functional peer in Australia.

TypeRegional player
Description

Australian national digital health commercialization organization. Comparable in mission (bridging research and commercial outcomes in health) but specialized in digital health rather than therapeutics, making it an adjacent rather than direct peer.

TypeBroad incumbent
Description

Australian Government-funded Industry Growth Centre for the medical technology, biotechnology, and pharmaceutical sector. Operates the Biomedical Translation Bridge Program with BioCurate and UniQuest, making it a partner and a broader, well-funded peer in the same translation ecosystem.

TypeBroad incumbent
Description

Australia's largest life sciences venture fund, managing the Medical Research Commercialisation Fund. It sits one step downstream of BioCurate as a likely future investor or acquirer of BioCurate-validated spin-outs, and competes for the same translational deal flow at the funding stage.

8Queensland Emory Drug Discovery Initiative (QEDDI)
TypeDirect peer
Description

Drug discovery and translation initiative embedded in Queensland Brain Institute at the University of Queensland. Directly comparable as a university-based translational drug discovery entity and is explicitly cited in the background of BioCurate's Director of Small Molecule Therapeutics.

TypeDirect peer
Description

Australian node of the Centre for Commercialization of Regenerative Medicine, focused on translating cell and gene therapies and regenerative medicine. Co-hosted events with BioCurate and shares a similar translational mandate for early-stage biomedical research in Australia.

10Australian Translational Medicinal Chemistry Facility (ATMCF)
TypeDirect peer
Description

Translational medicinal chemistry capability at Monash University focused on early-stage drug discovery. Dr Raphael Rahmani, BioCurate's Director of Small Molecule Therapeutics, previously worked at ATMCF, illustrating direct institutional overlap with BioCurate's small molecule work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioCurate

Biotechnology Translation Servicesbiocurate.com

BioCurate is a not-for-profit joint venture of the University of Melbourne and Monash University that funds and advances early-stage biomedical research from these institutions into pre-clinical therapeutic candidates. It offers a Proof of Concept Fund (up to $500,000 per project), due diligence, and global industry linkages to academic researchers in Victoria, Australia.

What BioCurate does

BioCurate is an Australian not-for-profit joint venture, formed in 2019 by the University of Melbourne and Monash University with the support of the Victorian State Government, whose mission is to identify promising biomedical research discoveries from these institutions and advance them into high-quality pre-clinical candidates for novel human therapeutics. It is operationally independent, headquartered in Carlton, Melbourne, and staffed by a small team (1-10 employees) of senior drug development professionals whose collective track record includes more than 170 years of biotech/pharma experience, 13 INDs, 30 therapeutics currently in the clinic, and more than $2.4 billion in cumulative deal value.

BioCurate's core offering is a project evaluation and due diligence service combined with a Proof of Concept Fund that provides up to $500,000 per project to generate industry-standard experimental validation and de-risk early-stage therapeutic assets. Its active portfolio comprises four Portfolio projects and nine Proof of Concept projects spanning oncology, neurological disease, cardiovascular disease, and other indications. The organisation also publishes an extensive library of educational fact sheets covering IP strategy, target validation, antibody validation, FDA guidance, Target Product Profile construction, and valuation frameworks, and participates in industry events such as BIO International Convention and the Business of Regenerative Medicine Asia Pacific Symposium.

BioCurate does not earn commercial revenue in the traditional sense; it is funded by its founding universities and the Victorian State Government, supplemented by matching co-funding from the MTPConnect Biomedical Translation Bridge Program (up to $1 million per project). Its go-to-market is community-led and researcher-focused, engaging Monash and University of Melbourne investigators through information sessions, pipeline reviews, and a formal BioCurate Opportunity Assessment process, with the objective of licensing or spinning out industry-ready assets into the global biopharmaceutical pipeline.

BioCurate firmographics

Firmographics
Name
BioCurate
Legal name
BioCurate
Website
https://biocurate.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
BioCurate is a not-for-profit joint venture of the University of Melbourne and Monash University that funds and advances early-stage biomedical research from these institutions into pre-clinical therapeutic candidates. It offers a Proof of Concept Fund (up to $500,000 per project), due diligence, and global industry linkages to academic researchers in Victoria, Australia.
Ownership category
akta.pro rank

BioCurate industry classification

Industry
Product category
Biotechnology Translation Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)

Keywords

  • Drug development translation
  • Preclinical research services
  • Biomedical translation services
  • Therapeutic development support
  • Academic-industry bridge

Where BioCurate is headquartered

Location

Headquarters

HQ city
Parkville
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

BioCurate business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Not-for-profit translation entity: BioCurate is a purpose-built, not-for-profit company designed to help achieve impact from university research. They provide funding, expertise, and networks to translate discoveries into industry-ready assets. They do not generate revenue in the traditional sense but are operationally independent with support from founding universities and Victorian Government.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BioCurate product offering

Product offering

Core offering

BioCurate identifies promising biomedical research discoveries from Monash University and the University of Melbourne and advances them into high-quality pre-clinical candidates for novel human therapeutics. The company provides funding (Proof of Concept Fund up to $500,000), expert evaluation services, and access to global biopharmaceutical networks to translate early-stage academic discoveries into industry-ready therapeutic assets.

Product overview

BioCurate is a not-for-profit joint venture between Monash University and the University of Melbourne, supported by the Victorian State Government, that provides translational drug development services. The company offers a Proof of Concept Fund (up to $500,000 for early-stage validation), manages a portfolio of therapeutic projects spanning oncology and neurological diseases, and provides educational resources including fact sheets on IP strategy, target validation, unmet medical need, FDA guidance, and drug development best practices. BioCurate's core offering is its project evaluation and due diligence services that bridge academia and industry.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proof of Concept Fund A funding program that supports early-stage therapeutic projects with up to $500,000 to provide industry-standard experimental validation, generate compelling data, de-risk projects, and propel them to the next value inflection point. Targeted at researchers from Monash University, University of Melbourne, and affiliated Medical Research Institutes.
  • Project Evaluation and Due Diligence Services Formal, rigorous process for project review and investment decision-making including initial screening, investigator meetings, due diligence, and Investment Committee review for therapeutic development projects. Targeted at academic researchers submitting therapeutic candidates for advancement.

Quantifiable outcome

  • More than 170 years of combined biotech/pharma industry experience
  • +3 more outcomes

Companies that use BioCurate

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

BioCurate technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioCurate partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • MTPConnectcoreStrategic or Co-development Partner · 1 February 2020MTPConnect operates the Biomedical Translation Bridge (BTB) Program in partnership with BioCurate, UniQuest, Medical Device Partnering Program, and Bridge/BridgeTech programs. The BTB Program provides up to $1 million in matching funding to nurture translation of new therapies, technologies, and medical devices through proof of concept.
  • UniQuestcoreStrategic or Co-development PartnerUniQuest is a partner in the Biomedical Translation Bridge (BTB) Program operated by MTPConnect, working with BioCurate and other partners to support translation of therapeutic discoveries.
  • Medical Device Partnering ProgramcoreStrategic or Co-development PartnerPart of of the BTB Program ecosystem supporting translation of medical technologies alongside therapeutics.
  • CCRM AustraliaminorStrategic or Co-development PartnerCCRM Australia co-hosted the Business of Regenerative Medicine Asia Pacific Symposium with NSW Stem Cell Network. BioCurate CEO presented at this event focused on regenerative medicine translation.
  • NSW Stem Cell NetworkminorStrategic or Co-development PartnerCo-host of Business of Regenerative Medicine Asia Pacific Symposium with CCRM Australia, bringing together organizations in the regenerative medicine field.
  • Monash UniversitycoreStrategic or Co-development PartnerFounding partner of BioCurate joint venture. Contributes research discoveries and academic expertise to the translation partnership.
  • University of MelbournecoreStrategic or Co-development PartnerFounding partner of BioCurate joint venture. Contributes research discoveries and academic expertise to the translation partnership.
  • Global biopharmaceutical companiescoreStrategic or Co-development PartnerBioCurate has developed linkages with key global biopharmaceutical companies, providing valuable advice and insight to guide research and give projects the best opportunity to progress in the translation process.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

BioCurate competitors and assessment

Company assessment

Others

  • Exopharm: Australian biotech spun out of Monash University and a former employer of BioCurate's Head of Drug Development, Chacko Joseph. It illustrates the type of spin-out entity that BioCurate's translation model is designed to generate and support.
  • Therapeutic Innovation Australia (TIA): National infrastructure provider supporting translational research capabilities across Australia. It is an enabler of the same translational ecosystem BioCurate operates in, rather than a direct competitor, but provides comparable services (capability access, project support) to overlapping researcher segments.

Regional players

  • Medical Device Partnering Program (MDPP): Flinders University-based program that helps Australian researchers and clinicians translate medical device concepts. It is a co-partner in the BTB Program with BioCurate and UniQuest and operates a comparable academia-industry bridging model in the medical device niche.
  • ANDHealth: Australian national digital health commercialization organization. Comparable in mission (bridging research and commercial outcomes in health) but specialized in digital health rather than therapeutics, making it an adjacent rather than direct peer.

Direct peers

  • UniQuest: University of Queensland's main commercialization and translation entity. Operates the same academia-to-industry bridge model as BioCurate and is a co-partner in MTPConnect's BTB Program, making it the closest direct functional peer in Australia.
  • Queensland Emory Drug Discovery Initiative (QEDDI): Drug discovery and translation initiative embedded in Queensland Brain Institute at the University of Queensland. Directly comparable as a university-based translational drug discovery entity and is explicitly cited in the background of BioCurate's Director of Small Molecule Therapeutics.
  • CCRM Australia: Australian node of the Centre for Commercialization of Regenerative Medicine, focused on translating cell and gene therapies and regenerative medicine. Co-hosted events with BioCurate and shares a similar translational mandate for early-stage biomedical research in Australia.
  • Australian Translational Medicinal Chemistry Facility (ATMCF): Translational medicinal chemistry capability at Monash University focused on early-stage drug discovery. Dr Raphael Rahmani, BioCurate's Director of Small Molecule Therapeutics, previously worked at ATMCF, illustrating direct institutional overlap with BioCurate's small molecule work.

Broad incumbents

  • MTPConnect: Australian Government-funded Industry Growth Centre for the medical technology, biotechnology, and pharmaceutical sector. Operates the Biomedical Translation Bridge Program with BioCurate and UniQuest, making it a partner and a broader, well-funded peer in the same translation ecosystem.
  • Brandon BioCatalyst: Australia's largest life sciences venture fund, managing the Medical Research Commercialisation Fund. It sits one step downstream of BioCurate as a likely future investor or acquirer of BioCurate-validated spin-outs, and competes for the same translational deal flow at the funding stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

BioCurate social profiles

Digital presence

BioCurate financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioCurate leadership team

Management profile

Number of profiles

Profiles9 records

BioCurate funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioCurate M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCurate

What does BioCurate do?

BioCurate identifies promising biomedical research discoveries from Monash University and the University of Melbourne and advances them into high-quality pre-clinical candidates for novel human therapeutics. The company provides funding (Proof of Concept Fund up to $500,000), expert evaluation services, and access to global biopharmaceutical networks to translate early-stage academic discoveries into industry-ready therapeutic assets.

Is BioCurate a public or private company?

BioCurate is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was BioCurate founded?

BioCurate was founded in 2019. It employs 1 to 10 people.

Where is BioCurate based?

BioCurate is headquartered in Parkville, Australia, in the Oceania region.

How does BioCurate make money?

One revenue line is on record: not-for-profit translation entity.

Who are BioCurate's main competitors?

Others on record are Exopharm and Therapeutic Innovation Australia (TIA). Regional players are Medical Device Partnering Program (MDPP) and ANDHealth. Direct peers are UniQuest, Queensland Emory Drug Discovery Initiative (QEDDI), CCRM Australia and Australian Translational Medicinal Chemistry Facility (ATMCF). Broad incumbents are MTPConnect and Brandon BioCatalyst.

Does BioCurate have an API?

No public API is recorded for BioCurate.

What industry is BioCurate in?

BioCurate's product category is Biotechnology Translation Services. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals